RESUMO
This study identifies a new chronic form of immune neutropenia in the young with or without detectable indirect anti-neutrophil antibodies, characterized by mild/moderate neutropenia low risk of severe infection (14%), tendency to develop autoimmune phenomena over the course of the disease (cumulative incidence of 58.6% after 20 years of disease duration), leukopenia, progressive reduction of absolute lymphocyte count and a T- and B-cell profile similar to autoimmune disorders like Sjogren syndrome, rheumatoid arthritis, and systemic lupus erythematosus (increased HLADR+ and CD3 + TCRγδ cells, reduced T regulatory cells, increased double-negative B and a tendency to reduced B memory cells). In a minority of patients, P/LP variants related to primary immuno-regulatory disorders were found. This new form may fit the group of "Likely acquired neutropenia," a provisional category included in the recent International Guidelines on Diagnosis and Management of Neutropenia of EHA and EUNET INNOCHRON ACTION 18233. The early recognition of this form of neutropenia would help clinicians to delineate better specific monitoring plans, genetic counseling, and potentially targeted therapies.
Assuntos
Artrite Reumatoide , Doenças Autoimunes , Lúpus Eritematoso Sistêmico , Neutropenia , Trombocitopenia , Humanos , Neutropenia/etiologia , Neutropenia/terapia , Doenças Autoimunes/complicações , Lúpus Eritematoso Sistêmico/complicações , Trombocitopenia/complicaçõesRESUMO
AIM: There is no wide consensus in the literature on the clinical significance and management of symptomatic and asymptomatic polyps. Aims of the study are to evaluate frequency of premalignant and malignant histo-pathologic features in endometrial polyps resected hysteroscopically and identify clinical parameters able to predict final histopathologic diagnosis. METHODS: Clinical data and pathologic report of 90 consecutive operative hysteroscopies performed on women with endometrial polyps were collected. Frequency of premalignant and malignant histopathologic features on the polyps were calculated and relation to clinical risk factors analyzed. RESULTS: The frequency of premalignant and malignant histopathologic features in polyps was 6.7% and 2.2% respectively. Owing to the small sample size no statistical analysis to detect clinical risk factor for premalignant or malignant histopathologic features could be performed. CONCLUSION: Frequency of premalignant and malignant histopathologic features in symptomatic and asymptomatic patients is not negligible. Reported clinical risk factors for malignant degeneration of endometrial polypoid lesions are the same as those reported for endometrial cancer and are very common in patients with endometrial polyps. Every endometrial polyp should be resected.
Assuntos
Neoplasias do Endométrio/epidemiologia , Neoplasias do Endométrio/cirurgia , Pólipos/epidemiologia , Pólipos/cirurgia , Lesões Pré-Cancerosas , Adulto , Idoso , Idoso de 80 Anos ou mais , Neoplasias do Endométrio/patologia , Feminino , Humanos , Pessoa de Meia-Idade , Pólipos/patologia , Estudos Prospectivos , Fatores de RiscoRESUMO
Retinoids have been studied as chemopreventive agents in clinical trials due to their established role in regulating cell growth, differentiation and apoptosis in preclinical models. Experimental evidence suggests that retinoids affect gene expression both directly, by activating and/or repressing specific genes, and indirectly, by interfering with different signal transduction pathways. Induction of apoptosis is a unique feature of fenretinide, the most widely studied retinoid in clinical trials on breast cancer chemoprevention due to its selective accumulation in breast tissue and to its favourable toxicological profile. In a phase III breast cancer prevention trial, fenretinide showed a durable trend to a reduction of second breast malignancies in premenopausal women. This pattern was associated with a favourable modulation of circulating IGF-I and its main binding protein (IGF-binding protein-3, IGFBP-3), which have been associated with breast cancer risk in premenopausal women in different prospective studies. In a subsequent biomarker study on premenopausal women who had participated in the phase III trial, high IGF-I and low IGFBP-3 baseline levels were found to predict second breast cancer risk, although the magnitude of their changes during treatment did not fulfil the requirements for suitable surrogate end-point biomarkers. In postmenopausal women, fenretinide did not reduce second breast cancer incidence, nor did it induce significant modulation of the IGF system. Similarly, fenretinide was not found to affect risk biomarkers significantly in early postmenopausal women on hormone replacement therapy, who are at increased risk of developing breast cancer. Biomarker studies of fenretinide alone or in combination with different nuclear receptor ligands are being conducted. In particular, clinical trials of fenretinide and tamoxifen have proved to be feasible, and this combination appears to be safe and well tolerated in high-risk women, especially when low-dose tamoxifen is employed. Novel retinoid X receptor-selective retinoids, or rexinoids, have been shown to suppress the development of breast cancer in several animal models with minimal toxicity, and are being intensively studied either alone or in combination with selective oestrogen receptor modulators, both in vitro and in vivo. The rexinoid, bexarotene, has recently been approved for the treatment of patients with cutaneous T-cell lymphoma, and a biomarker trial with bexarotene in women with high breast cancer risk is currently underway.
Assuntos
Antineoplásicos/uso terapêutico , Neoplasias da Mama/prevenção & controle , Retinoides/uso terapêutico , Ensaios Clínicos como Assunto , HumanosRESUMO
Acute lymphoblastic leukemia (ALL) is the most frequent malignancy of childhood. Although therapeutical advances have been achieved, some ALL subgroups still fare poorly. CD1d is a monomorphic molecule that provides a suitable target for immunotherapy in view of the characterization of a glycolipid, alpha-galactosylceramide (alpha-GalCer), capable of being presented to CD1d-restricted T cells with cytotoxic potential. We investigated CD1d expression in 80 pediatric B-cell precursor (BCP) ALL cases defined according to immunophenotype, cytogenetic features and age at onset. CD1d was detected on ALL cells in 15% of the patients. CD1d+ ALLs were significantly associated with infant leukemia, pro-B phenotype and mixed-lineage leukemia (MLL)/AF4 gene rearrangement. Accordingly, overall survival of patients with CD1d+ ALL was significantly shorter. CD1d+ leukemic blasts were able to present alpha-GalCer via CD1d to cytotoxic CD1d-restricted T cells, which induced apoptosis of ALL cells that was inhibited by mAb to CD1d. CD1d+ blasts loaded with alpha-GalCer elicited cytokine secretion by CD1d-restricted T cells. Analysis of bone marrow (BM) cells derived from normal donors revealed that CD19+/CD1d+ cells were mostly mature B lymphocytes. However, a minority of BCPs expressed CD1d. Thus, expression of CD1d in ALL cases heralds an adverse prognosis but may provide a therapeutic tool.
Assuntos
Antígenos CD1/metabolismo , Células-Tronco Hematopoéticas/metabolismo , Leucemia-Linfoma Linfoblástico de Células Precursoras/metabolismo , Leucemia-Linfoma Linfoblástico de Células Precursoras/patologia , Antígenos CD1d , Linfócitos B/citologia , Biomarcadores Tumorais/metabolismo , Comunicação Celular , Linhagem Celular , Criança , Galactosilceramidas/metabolismo , Células-Tronco Hematopoéticas/citologia , Humanos , Lactente , Células Matadoras Naturais/citologia , Células Matadoras Naturais/metabolismo , Leucemia-Linfoma Linfoblástico de Células Precursoras/mortalidade , Valor Preditivo dos Testes , Prognóstico , Taxa de SobrevidaRESUMO
The genotyping of the hepatitis C virus (HCV) by viral nucleic acids sequencing allows accurate epidemiological evaluation of a cohort of patients suffering from HCV-related chronic hepatopathy. The identification of viral isolates, which can be generally associated with hepatic damage or, vice versa, which are more responsive to pharmacological treatment, might enhance clinical interest on the nature of the infecting genotypes. We, therefore, draw attention to those viral genotypes that are characterised by significantly high or altered viremic and enzymatic levels.
Assuntos
Variação Genética , Hepacivirus/isolamento & purificação , Hepatite C Crônica/epidemiologia , Regiões 5' não Traduzidas/genética , Adulto , Idoso , Estudos de Coortes , Feminino , Genótipo , Hepacivirus/genética , Hepatite C Crônica/patologia , Hepatite C Crônica/virologia , Humanos , Fígado/patologia , Hepatopatias/epidemiologia , Hepatopatias/patologia , Hepatopatias/virologia , Masculino , Pessoa de Meia-Idade , RNA Viral/análise , RNA Viral/sangue , Análise de Sequência de DNA , Carga ViralRESUMO
HCV genotyping by nucleic acid sequencing emphasizes the difficulties involved in carrying out a more precise determination of the infectant viral population, probably due in part to the finding of still unknown isolates. Signs of heterogeneity in the genotype composition of the viral quasi-species and its evolutionary dynamism over time, together with the role played by some, more potentially aggressive, isolates in causing hepatic damage, encourage a more in-depth study of such topics.
Assuntos
Hepacivirus/genética , Hepatite C/epidemiologia , Hepatite C/virologia , Alanina Transaminase/sangue , Aspartato Aminotransferases/sangue , DNA Viral/análise , Heterogeneidade Genética , Genótipo , Hepacivirus/isolamento & purificação , Humanos , Carga ViralRESUMO
This study aimed to evaluate the prevalence of asthma and rhinitis in schoolchildren living in the Genoa area by using a validated questionnaire and to investigate the prevalence of sensitizations using skin prick tests. An ATS modified questionnaire was given to 781 schoolchildren (all of them aged between 11 and 14 years) resident in the Genoa area. The main outcome of the present survey demonstrates a high prevalence of sensitized children (40.7%). Asthma and rhinitis prevalences are very high, mainly concerning the lifetime diagnosis. Actual asthma prevalence is about 6%, confirming ISAAC results, but rhinitis prevalence is notably higher and there is no difference between seasonal and perennial forms. Mites are the most important cause of sensitization and pollens are more frequently the cause of polysensitization. A distinct percentage of the asthmatic children and a higher percentage of rhinitic children are nonallergic. On the other hand, about one third of the sensitized children are without symptoms: They may be considered as subjects at risk of developing clinical respiratory diseases later. In conclusion, this study shows the importance of evaluating the existence of atopy, since there are many subjects with asthma and rhinitis who are nonallergic, and subjects at risk of developing respiratory allergies may be detected.
Assuntos
Poluentes Atmosféricos/imunologia , Asma/etiologia , Rinite Alérgica Perene/etiologia , Adolescente , Alérgenos/efeitos adversos , Alérgenos/imunologia , Animais , Asma/epidemiologia , Criança , Proteção da Criança , Feminino , Humanos , Imunização , Itália/epidemiologia , Masculino , Ácaros/imunologia , Pólen/efeitos adversos , Pólen/imunologia , Prevalência , Rinite Alérgica Perene/epidemiologia , Testes CutâneosRESUMO
The development of a glucose sensor suitable for use with whole blood is described. It is based on anodic oxidation at +700 mV of hydrogen peroxide with a platinum electrode covered with a gas permeable membrane. Glucose reacts with glucose oxidase immobilised on the external side of the membrane, and forms hydrogen peroxide which is able to cross the gas permeable membrane due to its high vapour tension, while other electroactive substances that are important interferents are completely blocked. This principle was discovered several years ago but no practical application was presented up to now. Therefore in this work a number of different commercial membranes were tested, in order to obtain a resistant, rapidly responding and interference free sensor to be used in conjunction with a blood gas measurement apparatus. Coimmobilisation of glucose oxidase and catalase was found to be useful for fast response and recovery of the electrode. Using some of the tested membranes, the linearity range is 1-15 mM, CV 5%, response time 90 s, recovery time for the next sample 120 s. The membrane's working life is 2-3 weeks.
RESUMO
BACKGROUND: It has been reported that women with an inherited deficiency of antithrombin, protein C, or protein S have an increased risk for developing venous thromboembolic disease during pregnancy and the postpartum period. However, because the available data on risk are flawed, it is difficult to define a rational, efficacious, and safe policy about prophylaxis for venous thromboembolism in these women. OBJECTIVE: To determine the frequency of venous thromboembolism during pregnancy and the postpartum period in women with heritable deficiencies of anticoagulant factors. DESIGN: Retrospective cohort study. SETTING: University outpatient clinics in the Netherlands and Italy. PARTICIPANTS: 129 otherwise asymptomatic female family members of patients with a history of venous thromboembolism and an established deficiency of antithrombin, protein C, or protein S. MEASUREMENTS: Medical history, with specific attention to episodes of venous thromboembolism and obstetric history, was taken. The anticoagulant factor status of the study participants was determined. If a patient had an episode of venous thromboembolism, subsequent pregnancies in that patient were not analyzed. RESULTS: Of the 129 women who participated in the study, 60 had anticoagulant factor deficiency and 69 did not. In the nondeficient group, 198 pregnancies occurred; 1 of these (0.5%) was complicated by an episode of venous thromboembolism during the postpartum period. In the deficient group, 169 pregnancies occurred; 7 of these (4.1%) were complicated by an episode of venous thromboembolism during the third trimester of pregnancy (2 pregnancies [1.2%]) and the postpartum period (5 pregnancies [3.0%]). The risk for venous thromboembolism was increased eightfold in deficient women compared with nondeficient women (hazard ratio, 8.0 [95% CI 1.2 to 184]). CONCLUSIONS: Anticoagulant factor-deficient women have an increased risk for venous thromboembolism during pregnancy and the postpartum period. Although data from an appropriate randomized clinical trial are lacking, the frequency of venous thromboembolism seen in deficient women might justify the use of anticoagulative prophylaxis during the third trimester of pregnancy and the postpartum period.
Assuntos
Deficiência de Antitrombina III , Complicações Cardiovasculares na Gravidez/epidemiologia , Deficiência de Proteína C , Deficiência de Proteína S/complicações , Transtornos Puerperais/epidemiologia , Tromboembolia/epidemiologia , Adolescente , Adulto , Estudos de Coortes , Feminino , Heparina de Baixo Peso Molecular/uso terapêutico , Humanos , Incidência , Recém-Nascido , Gravidez , Complicações Cardiovasculares na Gravidez/sangue , Complicações Cardiovasculares na Gravidez/prevenção & controle , Transtornos Puerperais/sangue , Transtornos Puerperais/prevenção & controle , Estudos Retrospectivos , Fatores de Risco , Tromboembolia/sangue , Tromboembolia/prevenção & controleRESUMO
The role of oral contraceptives as a triggering factor for thrombosis in patients with lupus anticoagulant (LA) and/or anticardiolipin antibodies (ACA) has not yet been established. We describe the cases of three women aged 19, 29 and 48 years who developed venous thrombosis after 16 +/- 3.4 (mean +/- SD) cycles of oral contraceptives. They were all asymptomatic before taking the pill. Two patients subsequently developed venous and/or arterial recurrence of thrombosis. Laboratory studies performed after the diagnosis of thrombosis, showed the presence of LA and elevated levels of ACA (IgG and IgM) in all three patients. None of these patients had autoimmune diseases and therefore appeared to have a primary antiphospholipid antibody syndrome. The three patients belonged to a group of 45 young females who experienced their first thrombotic event while taking the pill. This group had a similar prevalence (8%) for antithrombin deficiency and antiphospholipid antibodies. We surmise that some of the women who developed venous thrombosis while taking the pill might have an undetected primary antiphospholipid syndrome.
PIP: In Italy, the University of Padua Hospital has treated 45 women for venous and/or arterial thrombosis during oral contraceptive (OC) therapy. Among the 38 who had no other risk factors for thrombosis, 8% had antiphospholipid antibodies. 3 patients featured in the cases were asymptomatic before beginning OC use. All 3 had their first thrombotic event during OC use. They developed thrombosis after 16 cycles of OCs. The first case (age 19) developed thrombotic occlusion on the left side of her body, especially her left leg after about 18 cycles of OC use (0.03 mg ethinyl estradiol and 0.075 mg gestodene). One month after beginning oral anticoagulant therapy physicians found antiphospholipid antibodies (i.e., the presence of lupus anticoagulant and increased levels of anticardiolipin antibodies). She later developed other thrombotic events despite anticoagulant therapy. The second case (age 35) first experienced a thrombotic event at the age of 29 after about 18 cycles of a sequential 3-phase combined OC. She was not put on long-term anticoagulant therapy at the time. 2 years later, she again experienced thrombosis in the same leg. She was put on oral anticoagulant therapy until age 33, when she wanted to become pregnant. She was then put on acenocumarol therapy. Her pregnancy ended in miscarriage at 8-10 weeks gestation. She developed thrombosis in the left leg 6 months later. Hospital staff detected antiphospholipid antibodies. Case 3 (age 48) had had 2 full-term, normal pregnancies and no miscarriages. She developed thrombosis in the left leg after 12 cycles of OC use (0.03 mg ethinyl estradiol and 0.075 mg gestodene). She discontinued OC use and began anticoagulant therapy. Laboratory findings indicated antiphospholipid antibodies. All 3 cases had or had had a false positive reading for syphilis. They were diagnosed with primary antiphospholipid syndrome (PAPS). These findings suggest that normal women who develop thrombosis during OC use might have undetected PAPS.
Assuntos
Anticorpos Antifosfolipídeos/sangue , Anticoncepcionais Orais/efeitos adversos , Tromboflebite/induzido quimicamente , Tromboflebite/imunologia , Adulto , Anticorpos Anticardiolipina/sangue , Anticoagulantes/uso terapêutico , Feminino , Humanos , Inibidor de Coagulação do Lúpus/sangue , Pessoa de Meia-Idade , Recidiva , Tromboflebite/tratamento farmacológicoAssuntos
Exsudatos e Transudatos/metabolismo , Doença da Mama Fibrocística/metabolismo , Substâncias de Crescimento/metabolismo , Mama/metabolismo , Mama/patologia , Neoplasias da Mama/metabolismo , Neoplasias da Mama/patologia , Feminino , Doença da Mama Fibrocística/patologia , Humanos , Hiperplasia/metabolismo , Hiperplasia/patologiaRESUMO
Hereditary deficiencies of the naturally occurring anticoagulants are well recognized conditions predisposing to recurrent venous thromboembolism. Since thrombotic phenomena have been implied as a cause of abortion and stillbirth, we hypothesized that these deficiencies increase the risk of fetal demise. A group of 129 female subjects who had been pregnant at least once and who had a family member with documented venous thrombosis associated with a deficiency of AT, PC or PS were studied. We first assessed the obstetric history and subsequently determined the deficiency status. In the 60 deficient subjects 42 (22.3%) of the 188 pregnancies resulted in miscarriage or stillbirth as compared to 23 (11.4%) of the 202 pregnancies in the 69 non-deficient subjects. The relative risk of abortion and stillbirth per pregnancy for deficient women as compared to non-deficient women was 2.0 (95% C.I. 1.2-3.3).
Assuntos
Aborto Espontâneo/sangue , Deficiência de Antitrombina III , Morte Fetal/sangue , Deficiência de Proteína C , Deficiência de Proteína S/complicações , Aborto Espontâneo/etiologia , Feminino , Morte Fetal/etiologia , Humanos , Gravidez , Fatores de RiscoRESUMO
The intracystic electrolyte content is generally used to identify different breast cyst subpopulations: cysts containing high K+ levels have been associated with an increased risk of subsequent breast cancer. In order to define whether other biochemical features of breast cyst fluid (BCF) might further explain such an increased risk, we determined the content of epidermal growth factor (EGF), a known mitogenic factor for normal and transformed breast epithelium, in cysts of women with breast cancer or proliferative lesions of the breast (atypical ductal or lobular hyperplasia and proliferative disease without atypia). Median intracystic EGF levels were significantly higher in patients with breast cancer or atypical hyperplasia than in cysts of women without any clinical or instrumental evidence of proliferative disease chosen as controls (p < 0.05 and p < 0.01, respectively). In patients affected by proliferative disease without atypia, intracystic EGF levels were not different either from controls or from the other study groups. No significant difference among groups was observed in the prevalence of Na+/K+ < 3 cysts, this being the most frequently observed type of cysts in all groups except in that with proliferative disease without atypia. No significant difference in EGF levels between cysts ipsilateral or contralateral to the biopsy was observed within each histological group. Our results indicate that EGF levels are higher in cysts aspirated from breasts with an associated proliferative pathology, either benign or neoplastic. The determination of intracystic EGF, combined with that of electrolyte content, might help to identify a subset of patients with gross cystic disease of the breast at potentially higher risk of developing breast cancer.
Assuntos
Neoplasias da Mama/química , Mama/química , Fator de Crescimento Epidérmico/análise , Exsudatos e Transudatos/química , Doença da Mama Fibrocística/química , Adulto , Idoso , Idoso de 80 Anos ou mais , Estudos de Casos e Controles , Feminino , Humanos , Pessoa de Meia-Idade , Potássio/análise , Sódio/análiseRESUMO
We evaluated the presence and distribution of transforming growth factor-beta 1 (TGF-beta 1) in breast cyst fluid (BCF), and its relationship with intracystic epidermal growth factor (EGF). EGF and TGF-beta 1 were determined by radioimmunoassay on 47 BCFs (27 of the Na+/K+ < 3 type and 20 of the Na+/K+ > 3 type). As expected, EGF levels were inversely correlated with the Na+/K+ ratio, and were consequently higher in Na+/K+ < 3 cysts as compared with Na+/K+ > 3 cysts, (p < 0.005). By contrast, TGF-beta 1 levels were directly correlated with the Na+/K+ ratio (p < 0.01), being higher in Na+/K+ > 3 cysts, though not significantly (p = 0.057). A significant negative relationship was found between EGF and TGF-beta 1 concentration. When the analysis was performed separately in the 2 cyst sub-populations, EGF and TGF-beta 1 were found to be negatively and significantly correlated in Na+/K+ < 3 cysts only (p < 0.01). Our results demonstrate that Na+/K+ < 3 cysts contain high levels of EGF, a growth-stimulating factor, and very low levels of TGF-beta 1, a growth-inhibiting factor. This may provide an explanation for the higher risk of breast cancer observed in women with Na+/K+ < 3 cysts. Our results also suggest that EGF accumulation in this type of cysts might be regulated by TGF-beta 1.
Assuntos
Fator de Crescimento Epidérmico/análise , Exsudatos e Transudatos/química , Doença da Mama Fibrocística/química , Potássio/análise , Sódio/análise , Fator de Crescimento Transformador beta/análise , Feminino , HumanosRESUMO
A 42-year-old Italian woman presenting with spontaneous deep vein thrombosis of the right arm, was found to have inherited a deficiency of both protein S (PS) and heparin co-factor II (HC II). The two defects seemed to segregate independently, since her son exhibited only a HC II deficiency while one of her sisters manifested only the PS defect. All affected patients appeared heterozygous for one or other or both deficiency states. The proposita and her sister exhibited a congenital PS deficiency consisting of normal or near normal levels of total PS antigen and C4b-binding protein (C4b-BP) but a moderate reduction both of free PS antigen and of PS functional activity. In addition, the proposita and her son had half normal levels of HC II antigen and activity. Except for the proposita, all were asymptomatic. Inherited deficiencies either of PS or of HC II have been associated with thrombotic manifestations. Since the proposita had an inherited combined defect of the two proteins, severe thrombotic events might be expected. However, this was not found to be the case. The role of HC II deficiency in the pathogenesis of thrombosis whether alone or combined remains to be fully investigated.
Assuntos
Veia Axilar , Proteínas Inativadoras do Complemento , Glicoproteínas , Cofator II da Heparina/deficiência , Deficiência de Proteína S , Tromboflebite/genética , Adolescente , Adulto , Proteínas de Transporte/análise , Feminino , Cofator II da Heparina/genética , Humanos , Masculino , Pessoa de Meia-Idade , Linhagem , Proteína S/genética , Tromboflebite/sangueRESUMO
Hereditary deficiency of protein C, protein S or antithrombin III has been associated with an increased incidence of venous thrombosis or pulmonary embolism. The relationship between these deficiencies and the development of arterial thrombosis is a matter of current investigation. We retrospectively studied the occurrence of arterial thrombosis in 92 symptomatic patients belonging to a group of 160 with a confirmed diagnosis of hereditary deficiency of one of the physiologic clotting inhibitors. Seventeen of them experienced at least one arterial thrombotic event. This indicates that about one out of five of the symptomatic patients had experienced arterial thrombosis. The control group consisted of 92 sex and age matched (+/- 5 years) patients with no clotting deficiency who had experienced in the same period at least one episode of deep vein thrombosis or pulmonary embolism. Only one of them had developed arterial thrombosis. Ischemic stroke, myocardial infarction, upper and lower limb arterial thrombosis, and mesenteric artery occlusion occurred regardless of the type of defect taken into account; mean age of about 37.05 +/- 23 years (mean +/- SD). In some cases, arterial thrombosis was fatal. The overall number of venous thrombotic events in the 92 symptomatic patients of this study was much higher than that of arterial thrombosis, with a ratio of 24 to 1. The use of long-term anticoagulant therapy in our group of patients seemed to be able to prevent recurrences of both arterial and venous thrombosis.